Malaria still poses a major burden on human health around the world, especially in endemic
areas. Plasmodium resistance to several antimalarial drugs has been one of the major …

Increased tolerance of Plasmodium falciparum to front-line artemisinin antimalarials (ARTs)
is associated with mutations in Kelch13 (K13), although the precise role of K13 remains …

Emergence and spread of resistance in Plasmodium falciparum to the frontline treatment
artemisinin-based combination therapies (ACTs) in the epicenter of multidrug resistance of …

Artemisinin and its derivatives (ART) are the cornerstone of malaria treatment as part of
artemisinin combination therapy (ACT). However, reduced susceptibility to artemisinin as …

Despite a significant decline in morbidity and mortality over the last two decades, in 2018
there were 228 million reported cases of malaria and 405000 malaria-related deaths …

Partial artemisinin resistance, defined in patients as a delayed parasite clearance following
artemisinin-based treatment, is conferred by non-synonymous mutations in the Kelch beta …

Keap1 (Kelch-like ECH-associated protein 1) is one of the major negative regulators of the
transcription factor Nrf2 (nuclear factor erythroid-2-related factor 2), which induces the …

Objectives Artemisinin (ART) resistance in Plasmodium is threatening the artemisinin
combination therapies—the first line of defence against malaria. ART resistance has been …

Mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) confer
resistance to several antimalarial drugs such as chloroquine (CQ) or piperaquine (PPQ), a …

Artemisinin-combined treatments are the recommended first-line treatment of Plasmodium
falciparum malaria, but they are being threatened by emerging artemisinin resistance …